Sotorasib vs. Adagrasib as Treatment for KRAS G12C Mutated NSCLC - Case Based Panel Discussion

preview_player
Показать описание
Drs. Ibiayi Dagogo-Jack, Joshua Reuss, Natalie Vokes, and Kathryn Arbour discuss three hypothetical cases of suspected cancer, from staging to treatment options, with the goal of giving an insider look into the diagnostic side of lung cancer.

In this video Drs. Dagogo-Jack, Reuss, and Arbour compare Sotorasib and Adagrasib as treatments for KRAS G12C Mutated NSCLC.

  1. GRACE - Global Resource for Advancing Cancer Education
  2. GRACE
  3. CancerGRACE
  4. oncology
  5. cancer
  6. education
Рекомендации по теме
Sotorasib vs. Adagrasib 0:04:13

Sotorasib vs. Adagrasib as Treatment for KRAS G12C Mutated NSCLC - Case Based Panel Discussion

Phase III trial 0:02:39

Phase III trial of divarasib versus adagrasib or sotorasib in KRAS G12C-m NSCLC

Sotorasib for KRAS 0:06:33

Sotorasib for KRAS G12C-Mutated Lung Cancer

Sotorasib drug-drug interactions 0:02:15

Sotorasib drug-drug interactions

How do doctors 0:02:31

How do doctors treat lung cancer with KRAS mutations?

Sotorasib,FDA,Lumakras amgen 510,non-small 0:04:20

Sotorasib,FDA,Lumakras amgen 510,non-small cell lung cancer

Current treatment strategies 0:01:10

Current treatment strategies KRASG12C–mutated NSCLC

SOTORASIB: NEW DRUG 0:01:38

SOTORASIB: NEW DRUG DESTROYS LUNG CANCER

Adagrasib for Previously 0:12:25

Adagrasib for Previously Treated KRAS G12C+ NSCLC - ASCO Lung Review 2022

Challenges of KRAS-targeting 0:01:25

Challenges of KRAS-targeting for lung cancer therapy

CodeBreak 200 | 0:44:57

CodeBreak 200 | Sotorasib | A Negligent trial that violated randomization!

Krystal 7 Study: 0:02:40

Krystal 7 Study: Adagrasib +/- Pembrolizumab for KRAS G12C+ NSCLC -Targeted Therapies in Lung Cancer

What are the 0:04:01

What are the latest developments in KRAS-mutant NSCLC?

Sotorasib med lovende 0:01:19

Sotorasib med lovende effekt

Advances in the 0:02:12

Advances in the management of KRAS-mutant NSCLC

ESMO highlights: KRAS 0:02:09

ESMO highlights: KRAS G12C inhibitors

Real-world outcomes by 0:05:14

Real-world outcomes by co-mutation status in KRAS G12C-mutant NSCLC

Targeting non-G12C KRAS 0:01:10

Targeting non-G12C KRAS mutations in NSCLC

Advances in the 0:01:27

Advances in the development of KRAS inhibitors

Phase II CodeBreak 0:03:01

Phase II CodeBreak 100 trial of sotorasib in advanced NSCLC

Combination therapies involving 0:01:18

Combination therapies involving KRAS G12C inhibitors in lung cancer

How will adagrasib 0:01:08

How will adagrasib fit into the treatment landscape of KRASG12-mutant NSCLC?

Sotorasib: first targeted 0:00:57

Sotorasib: first targeted approval for KRAS G12C mutated NSCLC

History of KRAS-targeting 0:03:20

History of KRAS-targeting in clinical trials